Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from AbSci ( (ABSI) ).
On August 12, 2025, Absci Corporation announced its second quarter financial results and business updates, highlighting a strengthened balance sheet with $64 million raised in July 2025, sufficient to fund operations into 2028. The company expanded its collaboration with Almirall, focusing on dermatological indications, and reported progress in its internal pipeline, including clinical trials for ABS-101 and ABS-201. Despite a net loss of $30.6 million for the quarter, Absci continues to advance its AI Drug Creation platform and anticipates further partnerships in 2025.
The most recent analyst rating on (ABSI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.
Spark’s Take on ABSI Stock
According to Spark, TipRanks’ AI Analyst, ABSI is a Neutral.
AbSci’s overall stock score is primarily impacted by its weak financial performance, characterized by ongoing losses and cash flow challenges. However, the company’s strategic initiatives, such as AI-driven drug discovery and potential partnerships, along with positive corporate events, provide some optimism for future growth. Technical indicators and valuation metrics remain mixed, reflecting the company’s current transitional phase.
To see Spark’s full report on ABSI stock, click here.
More about AbSci
Absci is a clinical-stage biopharmaceutical company that leverages generative AI and a synthetic biology data engine to rapidly design innovative therapeutics. The company’s Integrated Drug Creation™ platform is used to address challenging therapeutic targets, advancing its own pipeline of AI-designed therapeutics, including ABS-101 for inflammatory bowel disease and ABS-201 for hair regrowth. Absci collaborates with pharmaceutical, biotech, tech, and academic leaders and is headquartered in Vancouver, WA, with facilities in New York City and Switzerland.
Average Trading Volume: 4,579,138
Technical Sentiment Signal: Sell
Current Market Cap: $411.1M
Find detailed analytics on ABSI stock on TipRanks’ Stock Analysis page.